In chronic kidney disease (CKD), the Epo pathway appears to be involved not only in the onset of anemia but also in the regulation of CKD-mineral and bone disorder (CKD-MBD), a systemic disorder characterized by biochemical abnormalities, bone disorders, and vascular calcification. Here, EPO is linked to bone disorder.